Top Story

Surveillance imaging offers little benefit for DLBCL in first remission

Surveillance imaging offers little benefit for DLBCL in first remission
May 21, 2015

Surveillance imaging of asymptomatic patients with diffuse large B-cell lymphoma who are in remission may have little benefit yet substantial costs, according to study results.

Patients with diffuse large B-cell lymphoma (DLBCL) who achieve remission from front-line immunochemotherapy most commonly relapse within the first 2 years, but rarely relapse beyond the 5-year mark, according to study background. Although routine surveillance imaging during first remission is common, some experts have questioned its value and have argued there is no curative benefit to repeat imaging, the researchers wrote.

Wyndham H. Wilson, MD, PhD In the Journals

Circulating tumor DNA predictive biomarker for patients with DLCBL

May 19, 2015
The measurement of circulating tumor DNA detected microscopic disease recurrence before it could be detected on CT scans in patients with diffuse large B-cell lymphoma…
FDA News

FDA grants fast track status to AG-120 for IDH1-mutated AML

May 18, 2015
The FDA today granted fast track status to AG-120 for patients with acute myelogenous leukemia who harbor an IDH1 mutation, according to a press release from the…
In the Journals

Imatinib plus reduced-intensity chemotherapy shows promise for Ph+ALL

May 18, 2015
A reduced-intensity chemotherapy regimen combined with imatinib induced major molecular response rates comparable to the standard imatinib and hyper-CVAD regimen in…
CME CNE
Stem Cell Transplant for AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 3 Stem Cell Transplant for MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
Meeting News Coverage Video
Genome editing demonstrated wide application for blood disorders

Genome editing demonstrated wide application for blood disorders

January 5, 2015
SAN FRANCISCO — Ralph Green, MD, PhD, FRCPath, medical director of the UC Davis Health System Medical…
More »
CME
Hematology Oncology Case Consults

Diagnosis and Management of Hemophilia

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of the patient with hemophilia supplemented with a case…
More »
Scott F. Huntington, MD, MPH In the Journals

Surveillance imaging offers little benefit for DLBCL in first remission

May 21, 2015
Surveillance imaging of asymptomatic patients with diffuse large B-cell lymphoma who are in remission may have little benefit yet substantial costs…
Wyndham H. Wilson, MD, PhD In the Journals

Circulating tumor DNA predictive biomarker for patients with DLCBL

May 19, 2015
The measurement of circulating tumor DNA detected microscopic disease recurrence before it could be detected on CT scans in patients with diffuse…
FDA News

FDA grants fast track status to AG-120 for IDH1-mutated AML

May 18, 2015
The FDA today granted fast track status to AG-120 for patients with acute myelogenous leukemia who harbor an IDH1 mutation, according to a press…
In the Journals

Imatinib plus reduced-intensity chemotherapy shows promise for Ph+ALL

May 18, 2015
A reduced-intensity chemotherapy regimen combined with imatinib induced major molecular response rates comparable to the standard imatinib and…
In the Journals

Salvage therapies benefit patients with CLL after allogeneic SCT failure

May 14, 2015
Patients with chronic lymphocytic leukemia or Richter’s transformation who did not respond to or who progressed after allogeneic stem cell…
FDA News

FDA grants orphan drug designation to GMI-1271 for AML

May 14, 2015
The FDA today granted orphan drug designation to GMI-1271 for the treatment of patients with acute myeloid leukemia, according to a press release…
Meeting News CoveragePerspective

Elotuzumab combination prolongs PFS in relapsed multiple myeloma

May 13, 2015
The addition of elotuzumab to lenalidomide and dexamethasone significantly prolonged PFS in patients with relapsed or refractory multiple myeloma…
In the Journals

HBV monitoring key for lymphoma patients with resolved hepatitis

May 12, 2015
Research suggests monthly monitoring of viral DNA may help prevent reactivation-related hepatitis in some B-cell non-Hodgkin’s lymphoma…
Fabiana Ostronoff, MD In the JournalsPerspective

Improved AML prognosis with NPM1-positive FLT3-ITD-negative genotype contingent upon patient age

May 12, 2015
The presence of NPM1 mutations without FLT3-internal tandem duplication was associated with favorable prognosis in patients with acute myeloid…
In the Journals

Patients with atopic dermatitis may have slightly increased lymphoma risk

May 7, 2015
Patients with atopic dermatitis had a slightly increased risk of lymphoma, with the severity of atopic dermatitis a potentially significant risk…
More Headlines »
morganatic-roan
morganatic-roan